Peginterferon Beta-1A
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy.
Journal: Journal of autoimmunity
Published: November 07, 2025
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.
Journal: Journal of child neurology
Published: September 16, 2025
Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.
Journal: Neurodegenerative disease management
Published: July 15, 2025
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies.
Journal: Multiple sclerosis and related disorders
Published: September 17, 2024
Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
Journal: Multiple sclerosis and related disorders
Published: June 01, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: May 24, 2023
Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.
Journal: Multiple sclerosis and related disorders
Published: March 22, 2023
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Published: March 03, 2023
Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
Journal: Therapeutic advances in neurological disorders
Published: December 16, 2022
Recurrent encephalopathy associated with pegylated beta-interferon treatment.
Journal: Journal of neuroimmunology
Published: September 08, 2022
Multiple sclerosis clinical decision support system based on projection to reference datasets.
Journal: Annals of clinical and translational neurology
Published: April 07, 2022
Last Updated: 06/30/2026